A new study published in the journal of BMC Gastroenterology showed that dementia risk was higher in patients with metabolic ...

A pioneering research study published today in Cell Metabolism details how the hormone FGF21 (fibroblast growth factor 21) ...

A new blood test can predict the development of metabolic dysfunction-associated steatotic liver disease (MASLD) up to 16 ...

Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of ...

Pregnant women with MASLD have over three times the risk of preterm birth, according to Swedish registry data. This risk ...

Pregnant women with metabolic dysfunction-associated steatotic liver disease (MASLD) have an increased risk of giving birth prematurely and the risk increase cannot be explained by obesity, according ...

Wegovy (semaglutide) could offer a new option to treat severe liver disease based on new clinical trial evidence. The GLP-1 ...

Metabolic liver disease might not get as much attention as heart disease or diabetes, but it affects around one in four ...

Five plasma proteins may predict a patient’s risk for metabolic dysfunction-associated steatotic liver disease up to 16 years ...

Semaglutide and similar GLP-1 drugs are poised to become frontline treatments for a severe form of liver disease.

Bariatric surgery and GLP-1s conferred similar outcomes in mortality, adverse cardiovascular events and cirrhosis development ...